Noticias y Actividades de Third Rock Ventures

Ver el organigrama con sus 30 ejecutivos principales

Biografías más buscadas en Third Rock Ventures

• Chris Robinson, Chief Talent Officer
• Cary Pfeffer, Partner, Development Efforts
• Andrea van Elsas, Partner

Recientes movimientos de ejecutivos en Third Rock Ventures

• Dodzie Sogah, Venture Partner, ha dejado la empresa  (noticia publicada el 13 de mayo de 2025).

Crear su alerta
para seguir los movimientos de los ejecutivos en Third Rock Ventures.

Third Rock Ventures tiene 1.588 competidores entre los que se incluyen BlackRock (Estados Unidos), KKR (Estados Unidos) y Vanguard (Estados Unidos).

Popular M&A news in Fondo

• Seven2 has announced the acquisition of HRK Lunis  (publicado el 3 de abril de 2025).
• Fluent ha RIV Capital adquirido (publicado el 20 de diciembre de 2024).
• RIV Capital and Fluent have announced they will merge  (publicado el 14 de octubre de 2024)..

Otros contactos sugeridos en el sector Fondo

• Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer en Valor Equity Partners
• Salim Ramji - Chief Executive Officer and Director en Vanguard
• Hemant Taneja - Chief Executive Officer and Managing Director en General Catalyst Partners

Saber más sobre el sector Fondo

Últimos comunicados de prensa de Third Rock Ventures

• Septerna to Present at Jefferies Global Healthcare Conference - Thu, 05/29/2025 - 08:00
• Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference | Tango Therapeutics, Inc
• Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors | Tango Therapeutics, Inc
• Marea Therapeutics Appoints Charmi Turner as Senior Vice President, People & Culture | Marea Therapeutics
• Marea Therapeutics Announces Publication in The Lancet of Positive Data from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease | Marea Therapeutics
• Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones | Maze Therapeutics
• Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases - Wed, 05/14/2025 - 06:59
• Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results - Thu, 05/15/2025 - 16:01
• Marea Therapeutics Presents Positive Data from Phase 2a Clinical Trial of MAR001, Being Developed for Cardiovascular Disease, in Late-Breaking Oral Session at the 93rd EAS Congress | Marea Therapeutics
• BoardAppointment | SynnovationTx
• View more press releases Close

Redes sociales sobre Third Rock Ventures

• Third Rock Ventures en Wikipedia, Google News y Yahoo Finance
• Third Rock Ventures en LinkedIn, Twitter y YouTube